Cargando…

Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibition

INTRODUCTION: Synergistic effects have been discussed for tyrosine kinase (TKI) and immune checkpoint inhibitors (ICI). Primary resistance to TKI might disturb subsequent ICI effectiveness. The objective was to investigate, if primary resistance to 1st line TKI monotherapy predicts response to ICI i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Börner, J. H., Neuberger, S., Juengel, E., Ziewers, S., Dotzauer, R., Sparwasser, P., Höfner, T., Tsaur, I., Haferkamp, A., Mager, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517909/ https://www.ncbi.nlm.nih.gov/pubmed/37740836 http://dx.doi.org/10.1007/s12672-023-00791-3

Ejemplares similares

Telemedicine Online Visits in Urology During the COVID-19 Pandemic—Potential, Risk Factors, and Patients’ Perspective
por: Boehm, Katharina, et al.
Publicado: (2020)

First completely robot-assisted retroperitoneal nephroureterectomy with bladder cuff: a step-by-step technique
por: Sparwasser, P., et al.
Publicado: (2022)

High–Normal Preoperative Potassium Level Is Associated with Reduced 30–Day Morbidity and Shorter Hospital Stay after Radical Cystectomy
por: Borgmann, Hendrik, et al.
Publicado: (2022)

Robotic surgery can be safely performed for patients and healthcare workers during COVID‐19 pandemic
por: Sparwasser, Peter, et al.
Publicado: (2021)

Global change of surgical and oncological clinical practice in urology during early COVID-19 pandemic
por: Dotzauer, Robert, et al.
Publicado: (2020)

Pandemic Spread of COVID-19 Mutant Variants Will Facilitate Next-generation Sequencing Capacities for Personalised Medicine in Urologic Oncology
por: Borgmann, Hendrik, et al.
Publicado: (2021)

Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected
por: Duwe, Gregor, et al.
Publicado: (2023)

Robot-assisted simple prostatectomy versus open simple prostatectomy: a single-center comparison
por: Dotzauer, R., et al.
Publicado: (2020)

Assessment of a novel smartglass-based point-of-care fusion approach for mixed reality-assisted targeted prostate biopsy: A pilot proof-of-concept study
por: Sparwasser, P., et al.
Publicado: (2022)

Robotic surgery is safely performed for patients and healthcare workers during COVID-19 pandemic
por: Sparwasser, P., et al.
Publicado: (2020)

Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation
por: Duwe, Gregor, et al.
Publicado: (2023)

Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma
por: Brown, Jason R., et al.
Publicado: (2021)

Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned
por: Thomas, Christian, et al.
Publicado: (2016)

Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo
por: Juengel, Eva, et al.
Publicado: (2013)

Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway
por: Markowitsch, Sascha D., et al.
Publicado: (2022)

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
por: Juengel, Eva, et al.
Publicado: (2015)

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
por: Tsaur, Igor, et al.
Publicado: (2022)

Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion
por: Juengel, Eva, et al.
Publicado: (2016)

Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion
por: Juengel, Eva, et al.
Publicado: (2017)

Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K., et al.
Publicado: (2022)

Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro
por: Xie, Hui, et al.
Publicado: (2022)

Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis
por: Markowitsch, Sascha D., et al.
Publicado: (2020)

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients
por: Tsaur, Igor, et al.
Publicado: (2015)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A
por: Juengel, Eva, et al.
Publicado: (2014)

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
por: Denis, Marc G, et al.
Publicado: (2020)

Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer
por: Thomas, Anita, et al.
Publicado: (2021)

Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells
por: Makarević, Jasmina, et al.
Publicado: (2014)

Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2
por: Makarević, Jasmina, et al.
Publicado: (2014)

Amygdalin Influences Bladder Cancer Cell Adhesion and Invasion In Vitro
por: Makarević, Jasmina, et al.
Publicado: (2014)

HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
por: Juengel, Eva, et al.
Publicado: (2017)

Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro
por: Juengel, Eva, et al.
Publicado: (2019)

Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
por: Govindarajan, Ameish, et al.
Publicado: (2022)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
por: Yang, Yuanquan, et al.
Publicado: (2022)

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis
por: Wedel, Steffen, et al.
Publicado: (2011)

Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction
por: Zhao, Fuguang, et al.
Publicado: (2020)

Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer
por: Thomas, Anita, et al.
Publicado: (2022)

Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines
por: Resch, I., et al.
Publicado: (2021)

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade
por: Miller, Peter G., et al.
Publicado: (2020)

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Hong, Joohyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kek0tl3g8olfepcl5a7dpr9661